In four pancreatic cancer cell lines, 10 μM ICG-001 induced G1 arrest at 24 h. Annexin V/PI analysis at 48 h showed a significant apoptosis increase only in L3.6pl. CTNNB1 knockdown did not reproduce G1 arrest in AsPC-1, indicating that the cell-cycle response cannot simply be equated with β-catenin inhibition. [2]
ICG-001 increased migration in KHOS, MG63 and 143B osteosarcoma cells in an 8 h Boyden-chamber assay after 24 h pretreatment at 10 μM. Real-time assays in KHOS and 143B showed increased migration at 8 h but no significant difference at 24 h. These results argue against assuming a uniform anti-migratory effect. [3]
Purified CBP/β-catenin interaction assay
Biochemical assay · Purified CBP(1–111), p300(1–111), and β-catenin(647–781) [1]
At 100 μM, ICG-001 disrupted the CBP/β-catenin complex in the reported assay while the p300/β-catenin complex was retained. This single-concentration assay does not establish a binding Kd or universal target selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM
- Method
- Challenge of preformed protein complexes followed by anti-His immunoblot
- Reported limits
- Challenge duration and solvent for this purified-protein panel are not specified in the acquired caption/text.
Methods and source locations
Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001
Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.
Results: ICG-001 Specifically Interacts with CBP; Figure 2B and caption
CBP or p300 retained in β-catenin complexes: Purified CBP or p300 fragments (5 μg) with β-catenin fragment (5 μg); paired no-ICG-001 lanes — Results: ICG-001 Specifically Interacts with CBP; Figure 2B and caption
β-catenin/TCF reporter inhibition
Cell-based study · SW480 human colorectal carcinoma cells [1]
ICG-001 inhibited TOPFLASH with a reported IC50 of 3 μM, whereas the mutated-site FOPFLASH reporter was unaffected in the tested series. The IC50 is a cellular reporter endpoint, not a CBP binding constant.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 1B-C: 1.6, 3.1, 12, 25, 50 and 100 μM
- Method
- TOPFLASH/FOPFLASH dual-luciferase reporter assays
- Reported limits
- Treatment duration and solvent for Figure 1B-C are not specified in the acquired methods/caption; 24-hour conditions from Figure 3 were not borrowed.
Methods and source locations
Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001
Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.
Results: ICG-001 Antagonizes β-Catenin/TCF Transcription; Figure 1B-C; Methods: Transfection and Luciferase Assays
TOPFLASH activity: Dual luciferase; transfection normalization with pRL-null. Methods describe the mean of two independent experiments performed in duplicate. — Results: ICG-001 Antagonizes β-Catenin/TCF Transcription; Figure 1B-C; Methods: Transfection and Luciferase Assays
Mutated TCF-site FOPFLASH activity: Figure 1C versus no-compound baseline — Results: ICG-001 Antagonizes β-Catenin/TCF Transcription; Figure 1B-C; Methods: Transfection and Luciferase Assays
PDAC cell-cycle arrest and apoptosis controls
Cell-based study · AsPC-1, L3.6pl, PANC-1 and MiaPaCa-2 human pancreatic cancer cells; CTNNB1 perturbation comparison in AsPC-1 [2]
ICG-001 induced G1 arrest in all four lines. Apoptosis by annexin V/PI increased significantly only in L3.6pl. CTNNB1 knockdown did not reproduce G1 arrest in AsPC-1, limiting attribution of the cell-cycle response solely to β-catenin inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM ICG-001
- Exposure duration
- 24 h for cell-cycle and protein assays; 48 h for annexin V/PI and CTNNB1 comparison
- Method
- Flow cytometry and immunoblot
- Vehicle
- DMSO
- Co-treatment
- CTNNB1 or control siRNA (20 nM) comparison; staurosporine 500 nM is a separate apoptosis-positive control, not an ICG-001 combination efficacy result.
- Reported limits
- No exact DMSO percentage given for these cellular panels. Cell lines were not subsequently authenticated after receipt.
Methods and source locations
Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001
Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.
Figure 4A-D and caption; Results: ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling; Methods: Cell growth, proliferation and apoptosis assays, Gene Knockdown
Cell-cycle distribution: Propidium iodide flow cytometry; Figure 4C at 24 h and Figure 4D at 48 h. Figure 4D caption reports >75% β-catenin knockdown. One representative experiment of three replicates. — Figure 4A-D and caption; Results: ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling; Methods: Cell growth, proliferation and apoptosis assays, Gene Knockdown
Annexin V/PI-positive apoptosis: Annexin V/PI at 48 h, Figure 4B; separate 24 h immunoblots include staurosporine positive control and tubulin loading control (4A). — Figure 4A-D and caption; Results: ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling; Methods: Cell growth, proliferation and apoptosis assays, Gene Knockdown
Increased osteosarcoma cell migration
Cell-based study · Human KHOS, MG63 and 143B osteosarcoma cells [3]
After 24 h pretreatment with 10 μM ICG-001, Boyden-chamber migration increased in all three lines at the 8 h endpoint. Impedance-based migration increased at 8 h in KHOS and 143B but no longer differed significantly at 24 h. This is adverse, context-dependent evidence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 24 h pretreatment; migration monitored for 8 h by Boyden chamber or up to 24 h by impedance
- Method
- Boyden chamber and xCELLigence real-time migration
- Vehicle
- DMSO
- Reported limits
- Exact DMSO percentage and stereochemical purity not reported in the acquired cellular methods.
Methods and source locations
Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001
Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.
Results 2.3; Figure 5a-c and caption; Methods 4.1, 4.11-4.12, 4.15
Migrated cells relative to DMSO control: 8 h Boyden assay after 24 h pretreatment; DMSO set to 100%. Figure 5a means ± SD; KHOS n=3, MG63 n=2, 143B n=3, each performed in duplicate. — Results 2.3; Figure 5a-c and caption; Methods 4.1, 4.11-4.12, 4.15
Impedance migration cell index relative to vehicle: Figure 5b means ± SEM from three independent experiments, each in duplicate. MG63 could not be evaluated using this assay because of low migration. — Results 2.3; Figure 5a-c and caption; Methods 4.1, 4.11-4.12, 4.15